Why the study?
Does glucose-insulin-potassium (GIK) infusion improve cardiac function in patients with chronic ischaemic left ventricular dysfunction?
Does glucose-insulin-potassium (GIK) infusion improve cardiac function in patients with chronic ischaemic left ventricular dysfunction?
GIK infusion improves wall motion score, myocardial velocity, and end systolic volume in patients with viable myocardium and chronic ischemic left ventricular dysfunction, independent of hemodynamic changes.
No takes yet. Share an insight, caveat, or question.
Echo improvements with GIK should not change practice; leaves open outcome benefits in randomized trials.
Vincent Khoury (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: